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Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRASG12C). The mechanisms of acquired resistance to these
therapies are currently unknown.
METHODS

Among patients with KRASG12C -mutant cancers treated with adagrasib monother
apy, we performed genomic and histologic analyses that compared pretreatment
samples with those obtained after the development of resistance. Cell-based experiments were conducted to study mutations that confer resistance to KRASG12C
inhibitors.

Copyright © 2021 Massachusetts Medical Society.

RESULTS

A total of 38 patients were included in this study: 27 with non–small-cell lung
cancer, 10 with colorectal cancer, and 1 with appendiceal cancer. Putative mechanisms of resistance to adagrasib were detected in 17 patients (45% of the cohort),
of whom 7 (18% of the cohort) had multiple coincident mechanisms. Acquired
KRAS alterations included G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R, Y96C, and
high-level amplification of the KRASG12C allele. Acquired bypass mechanisms of
resistance included MET amplification; activating mutations in NRAS, BRAF,
MAP2K1, and RET; oncogenic fusions involving ALK, RET, BRAF, RAF1, and FGFR3;
and loss-of-function mutations in NF1 and PTEN. In two of nine patients with lung
adenocarcinoma for whom paired tissue-biopsy samples were available, histologic
transformation to squamous-cell carcinoma was observed without identification
of any other resistance mechanisms. Using an in vitro deep mutational scanning
screen, we systematically defined the landscape of KRAS mutations that confer
resistance to KRASG12C inhibitors.
CONCLUSIONS

Diverse genomic and histologic mechanisms impart resistance to covalent KRASG12C
inhibitors, and new therapeutic strategies are required to delay and overcome this
drug resistance in patients with cancer. (Funded by Mirati Therapeutics and others;
ClinicalTrials.gov number, NCT03785249.)
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K

RAS is one of the most commonly
mutated oncogenes in cancer. The KRAS
protein normally functions as a molecular
switch that cycles between an active, guanosine5′-triphosphate (GTP)–bound state and an inactive,
guanosine-5′-diphosphate (GDP)–bound form.
Oncogenic mutations in KRAS typically occur at
hotspots in the protein (e.g., codons 12, 13, and
61), increasing the steady-state levels of KRAS
proteins in the GTP-bound state that are capable
of driving protumorigenic signaling through
downstream effector pathways, such as the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways. Therapeutic targeting of mutant KRAS has proven
challenging because of its high affinity for nucleotide and the lack of tractable binding pockets
for small-molecule inhibitors.1,2 In the past several years, compounds have been identified that
bind covalently to cysteine 12 within the switch II
pocket of the GDP-bound form of the KRASG12C
protein, preventing oncogenic signaling and
causing potent tumor regressions in preclinical
models.3-7 KRASG12C mutations occur in approximately 13% of lung adenocarcinomas and approximately 3% of colorectal adenocarcinomas
and less commonly in cancers of the uterus,
pancreas, breast, bladder, cervix, and ovaries.8,9
In early-phase clinical trials, two potent, selective, and irreversible small-molecule KRASG12C
inhibitors have shown promising results in non–
small-cell lung cancer (NSCLC) and more modest efficacy in colorectal cancer: adagrasib
(MRTX849) and sotorasib (AMG510).6,7,10 An ongoing phase 1–2 study of adagrasib that involves
patients with KRASG12C -mutant cancer has shown
an objective response rate of 45% among patients with NSCLC11,12 and 17% among those
with colorectal cancer.13 Sotorasib was associated with an objective response rate of 37.1% and
a median progression-free survival of 6.8 months
among patients with NSCLC14 and a response
rate of 7.1% among those with colorectal cancer.10 Despite the clinical benefit that was observed for many patients treated with KRASG12C
inhibitors, acquired resistance to single-agent therapy eventually occurred in most patients. Little
is currently known about the clinical mechanisms of resistance to KRASG12C inhibition.6,7,15-17
Among patients with KRASG12C -mutant cancers
treated with adagrasib monotherapy in the
KRYSTAL-1 trial, we performed histologic and
n engl j med 384;25

genomic analyses of samples obtained at the
time of disease progression to identify mechanisms of resistance to adagrasib. Moreover, we
used a deep mutational scanning screen with a
library of KRASG12C missense variants to systematically define possible second-site mutations
that confer resistance to KRASG12C inhibition.

Me thods
Patients

Patients with KRASG12C -mutant cancers who had
disease progression while receiving adagrasib
monotherapy were included in this study. Acquired resistance to therapy was defined as stable disease for at least 12 weeks or a partial or
complete response followed by disease progression according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Institutional
review board–approved correlative studies were
performed at participating institutions before
adagrasib treatment and at the time of resistance to adagrasib.
Analysis of Resistance Mechanisms

Histologic features of available tissue-biopsy samples that were obtained at the time of acquired
resistance to adagrasib were compared with
those of samples obtained before adagrasib
treatment. Next-generation sequencing was performed on tissue samples or circulating tumor
DNA (ctDNA) obtained at the time of adagrasib
resistance, and the results were compared with
available results of tissue or plasma sequencing
before adagrasib treatment (Table S1 in the
Supplementary Appendix, available with the full
text of this article at NEJM.org). Genomic alterations were represented in relation to the wildtype reference coding sequence and according to
the variant allele frequency of each specific mutation.
In Vitro Validation of Drug Resistance

Individual resistance mutations were generated
by site-directed mutagenesis and transduced into
Ba/F3 cells.18 Ba/F3 cells that expressed the mutant or control KRASG12C alleles were treated with
adagrasib or sotorasib across the dose range,
and the area under the dose–response curve was
calculated for comparison of dose response
across alleles. Immunoblotting was performed
to assay biomarker response to KRASG12C inhibi-
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tion. The methods of validation are detailed in with NSCLC (Fig. 1A and Fig. S1), H95Q and
the Supplementary Appendix.
H95R mutations in 1 patient with colorectal cancer (Fig. 1B), R68S and H95D mutations in 1 paDeep Mutational Scanning
tient with NSCLC (Fig. 1C), and an H95R mutaDeep mutational scanning is an approach that tion in another patient with colorectal cancer
uses massively parallel sequencing to simultane- (Fig. 1D). In addition, activating mutations in
ously measure the functional effect of many KRAS, such as G12D, G12V, and G13D (each ocvariants in a protein in a single experiment.19,20 curring in trans on a separate KRAS allele than
We designed and synthesized a lentiviral variant the G12C allele) as well as G12R and Q61H
library that expressed nearly all possible distinct (status with respect to cis or trans position unable
alleles with a single amino acid substitution in to be assessed), were identified in several pathe KRASG12C backbone allele. We performed a tients (Figs. 1B through 1D and 2A and 2B and
positive-selection deep mutational scanning Fig. S2). In 1 patient, the G12C-mutant codon 12
screen for mutations in KRASG12C that confer re- (c.34G→T) apparently acquired an additional mutasistance to KRASG12C inhibition in Ba/F3 cells tion (c.36T→G), leading to a mutation from cystecultured for 7 days in the absence of interleu- ine to tryptophan (c.34_36 GGT→TGT→TGG, ultikin-3 and in the presence of one of two KRASG12C mately noted as a G12W mutation) (Fig. 1C and
inhibitors, MRTX1257 (a compound highly re- Fig. S2B), which conferred resistance to adagrasib.
lated to adagrasib)7 or sotorasib. Relative allele
Pathogenic mutations in other receptor tyroabundance at the screen end point was evaluat- sine kinase (RTK)–RAS–MAPK pathway members
ed, and z scores were calculated to define resis- were also detected in patients with acquired
tance mutations as those mutant alleles that resistance to adagrasib, including NRAS (Q61K
permitted cell proliferation in the context of in one patient), BRAF (V600E in two patients),
KRASG12C inhibitor treatment (see the Supple- MAP2K1/MEK1 (K57T in one patient, K57N in two
mentary Appendix).
patients, an I99_K104 deletion in one patient, and
an E102_I103 deletion in two patients), and EGFR
(A289V in one patient) (Figs. 1B through 1D and
R e sult s
2A and 2B). Oncogenic gene rearrangements
Mechanisms of Acquired Resistance to
emerged after treatment with adagrasib in three
Adagrasib
patients with colorectal cancer, including CCDC6A total of 38 patients treated with adagrasib who RET (Fig. 1B) and EML4-ALK (Fig. 2A). Numerous
initially had stable disease for at least 12 weeks oncogenic gene rearrangements were detected in
or an objective response to therapy followed by a single patient with colorectal cancer (Patient 6),
subsequent disease progression were included in including distinct fusions involving RAF1, BRAF,
this study: 27 patients had NSCLC, 10 had and FGFR3 (Fig. 2B and Fig. S3). In several pacolorectal cancer, and 1 had appendiceal cancer. tients, multiple mechanisms of resistance were
At the time of acquired resistance to adagrasib, identified simultaneously through ctDNA analytissue was available for analysis for 10 patients, sis (Figs. 1B through 1D and 2A and 2B).
and ctDNA was available for 32 patients; both
In two patients, high-level focal amplifications
tissue and ctDNA were obtained from 4 of these of the KRASG12C allele were identified in the
patients. In 32 of the 38 patients (84%), the adagrasib-resistant samples with no other idenoriginal KRASG12C mutation was identified at the tifiable resistance mechanisms (Fig. 2C and Fig.
time of adagrasib resistance. For the six in- S4). Acquired MET amplification was the only
stances in which KRASG12C mutation was not ob- potential genomic mechanism of adagrasib reserved at the time of resistance, only plasma was sistance identified in two other patients (Fig. 2D
available for analysis, and the lack of detection and Fig. S5). Lastly, in 2 of 10 patients (9 with
of this allele may reflect insufficient tumor NSCLC and 1 with colorectal cancer) from whom
shedding of ctDNA in those patients.
a repeat tissue-biopsy sample was obtained at the
Putative mechanisms of resistance to adagra- time of disease progression during adagrasib treatsib were identified in 17 of 38 patients (45%). ment, histologic transformation from adenocarciNovel acquired secondary KRAS mutations within noma to squamous-cell carcinoma was observed
the adagrasib-binding pocket were found in 4 pa- without any identifiable genomic mechanisms of
tients, including a Y96C mutation in 1 patient resistance (Fig. 2E and Fig. S6).
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Figure 1. Resistance to Adagrasib Conferred by Acquired KRAS Mutations.
Serial axial computed tomographic scans are shown for a patient with KRASG12C-mutant lung adenocarcinoma
(Panel A) who had a partial response to adagrasib followed by disease progression. A lung tumor biopsy at the time
of acquired resistance showed an acquired KRAS Y96C mutation. A patient with colorectal cancer (Panel B) showed
multiple mechanisms of adagrasib resistance, including mutations in KRAS H95Q, H95R, G12R/D/V, G13D, and
Q61H (listed twice owing to distinct c.183A→C and c.183A→T mutations leading to the same amino acid substitution); MAP2K1 K57N/T mutations; and a CCDC6-RET fusion. Pretreatment sequencing of RIT1 and PTEN was not
performed. In this patient, the pretreatment variant allele frequency (VAF) for KRASG12C was from tissue, whereas
the VAF at resistance was from circulating tumor DNA. A patient with lung adenocarcinoma (Panel C) was found
to have KRAS R68S, H95D, and G12V/W along with BRAF V600E mutations at the time of acquired resistance to
adagrasib. A patient with colorectal cancer (Panel D) showed KRAS H95R and G12D mutations as well as an activating MAP2K1 deletion. In Panels B through D, red coloring indicates KRAS alleles. ND denotes not detected.

Observed mechanisms of resistance to adagrasib are summarized in Figure 3. Among the 17
of 38 patients with putative resistance mechanisms identified, 9 (53%) had at least one acquired KRAS mutation or amplification. Furthermore, putative resistance mechanisms that did
not directly involve KRAS but were related to the
RAS signaling pathway were observed in 12 of
the 17 patients (71%). In addition, 7 of the 17
n engl j med 384;25

patients (41%) had more than one concurrent
potential resistance mechanism identified. In
our cohort, multiple resistance mechanisms appeared to be more common in colorectal cancer;
among patients with available ctDNA sequencing, 4 of 5 patients with colorectal cancer and 2
of 7 patients with NSCLC had multiple resistance alterations, although this difference was
not significant.
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Role of Drug-Binding Site Mutations

Figure 2 (facing page). Genetic and Nongenetic
Mechanisms of Resistance to Adagrasib.

Given the required covalent mode of adagrasib
binding to the cysteine at codon 12 in the
KRASG12C protein, the observed KRAS G12D/R/
V/W mutations would not be expected to bind
adagrasib or to be inhibited by the drug. We also
identified the KRAS R68S, H95D/Q/R, and Y96C
mutations within the switch II pocket where both
adagrasib and sotorasib bind (Fig. 4A and 4B).
Analysis of these residues in the x-ray crystallographic structure of adagrasib bound to KRASG12C
(6UT0)21 revealed that mutations at these positions
could result in disruption of noncovalent binding interactions of the drug (Fig. 4A and Figs. S7
through S9). By comparison, mapping of these
same residues onto the x-ray crystallographic
structure of sotorasib bound to the KRASG12C
protein (6OIM)6 suggested strong interactions of
R68 and Y96 with sotorasib but probably weaker interactions with the H95 residue, although

A patient with colorectal cancer (Panel A) was found to
have multiple acquired mutations in KRAS, EGFR, and
MAP2K1 and an EML4-ALK rearrangement. Multiple
oncogenic fusions (Panel B) involving FGFR3, BRAF,
and RAF1, along with activating mutations of KRAS,
NRAS, and MAP2K1, were detected in a patient with
colorectal cancer. A patient with colorectal cancer
(Panel C) was observed to have focal amplification of
the KRASG12C allele at the time of adagrasib resistance.
In Panels A through C, red coloring indicates KRAS alleles. Acquired focal MET amplification (Panel D) is
shown for a patient with lung adenocarcinoma. Focal
MYC amplification was also observed in both the pretreatment and post-resistance biopsies. The y axis shows
the log 2 ratio of copy number for tumor to paired normal tissue. Histologic transformation from lung adenocarcinoma to squamous-cell carcinoma (Panel E) was
observed at the time of adagrasib resistance in a patient for whom a genetic mechanism of resistance could
not be identified.
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Figure 3. Summary of Putative Mechanisms of Acquired Resistance to Adagrasib Treatment.
Of 38 patients with KRASG12C-mutant cancers, 17 had at least one putative resistance mechanism. A summary of
the genomic and histologic mechanisms of resistance among these 17 patients is shown in the comutation plot,
with each row indicating a patient and each column indicating a specific acquired alteration. Seven patients had
more than one putative resistance mechanism identified. AC denotes appendiceal cancer, CRC colorectal cancer,
ctDNA circulating tumor DNA, and NSCLC non–small-cell lung cancer.
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additional studies would be needed to quantify
the strength of these interactions (Fig. 4B).
To investigate the effect of these switch II
pocket mutations in KRASG12C on adagrasib and
sotorasib sensitivity, we generated double-mutant
2388
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G12C/Y96C

alleles of KRASG12C with the clinically observed
second-site mutations, including R68S, H95D,
H95Q, H95R, and Y96C. We exogenously expressed these double-mutant alleles or the control KRASG12C allele in the Ba/F3 cell line, a well-
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Resistance Mutations Revealed by Deep
Mutational Scanning

Figure 4 (facing page). Resistance to Adagrasib
or Sotorasib Conferred by Acquired Missense
Mutations in the KRASG12C Drug-Binding Site.
Putative second-site resistance mutations were mapped
onto crystal structures of KRASG12C bound to adagrasib
(Panel A) or sotorasib (Panel B). Shown are representative dose–response curves for Ba/F3 cells that were grown
in the absence of interleukin-3, that expressed the indicated KRASG12C variants, and that were treated for 5 days
with adagrasib (Panel C) or sotorasib (Panel D). The
curves represent means ±SE from at least three independent experiments. Immunoblots (Panel E) are shown for
extracellular signal-regulated kinase (ERK) phosphorylation levels (pERK1/2 T202/Y204) and KRAS total protein
levels from Ba/F3 cells that expressed KRASG12C or three
clinically observed resistance mutations: KRASG12C/H95D,
KRASG12C/H95R , and KRASG12C/Y96C . An immunoblot for
vinculin is shown as a loading control. Six-hour adagrasib or sotorasib treatment of cells that expressed sensitive but not insensitive alleles conferred suppression of
pERK and upward band shift of KRAS due to covalent
binding of the inhibitors. GDP denotes guanosine-5′diphosphate, and DMSO dimethyl sulfoxide.

established system for studying oncogene
dependence (Fig. S10).18 Ba/F3 cells that express
KRASG12C are highly sensitive to treatment with
either adagrasib or sotorasib and show dosedependent inhibition of downstream KRAS effector signaling (Fig. 4C through 4E). Expression of
all clinically observed switch II pocket mutations
(R68S, H95D, H95Q, H95R, and Y96C) conferred
marked resistance to adagrasib in Ba/F3 cells
(Fig. 4C). Similarly, expression of the G12C/R68S
and G12C/Y96C double mutants mediated resistance to sotorasib; in contrast, the G12C/H95D,
G12C/H95Q, and G12C/H95R mutants remained
sensitive to sotorasib (Fig. 4D). Biochemical analysis of the response to adagrasib in Ba/F3 cells
showed that the R68S, H95D/Q/R, and Y96C
second-site mutations in KRASG12C blocked drug
binding, as indicated by the absence of KRAS
band shift mediated by covalent drug binding,
and completely prevented the drug-mediated
suppression of RAS–MAPK signaling, as measured by sustained phosphorylated extracellular
signal-regulated kinase levels (Fig. 4E and Fig.
S11). On the other hand, the R68S and Y96C but
not the H95D/Q/R mutations mediated resistance to sotorasib in these biochemical assays.
Collectively, mutations that disrupt covalent or
potentially noncovalent drug binding can account
for clinical resistance to KRASG12C inhibition.
Moreover, differential drug-binding mechanisms
between adagrasib and sotorasib can lead to the
emergence of drug-specific resistance mutations.
n engl j med 384;25

We sought to define all possible secondary mutations in KRASG12C that can confer resistance to
KRASG12C inhibitors. Using a lentiviral library that
encoded nearly all possible alleles with a single
amino acid substitution within the KRASG12C backbone allele, we performed a positive-selection
screen in the Ba/F3 cell line for mutations that
cause resistance to two different KRASG12C inhibitors: sotorasib and MRTX1257, a compound
highly related to adagrasib with an identical
mode of binding (Figs. S12 through S14).7 Drugresistance mutations were defined as those that
enabled cell survival during treatment with a
KRASG12C inhibitor (Fig. 5 and Table S2). Multiple
mutations that were identified in the screen at
codons 12, 68, 95, and 96 conferred strong resistance to MRTX1257. Additional strong MRTX1257resistance mutations were detected at codons 8,
9, 64, 99, and 117. All clinically observed adagrasib-resistance mutations in KRASG12C scored as
strong resistance mutations in the MRTX1257
screen (Fig. 5 and Fig. S15). In the sotorasib
screen, numerous strong resistance mutations
were observed at codons 8, 9, 12, 96, and 117.
Patterns of MRTX1257 and sotorasib resistance
mutations were mapped onto existing structural
representations of KRASG12C bound to adagrasib
or sotorasib, respectively (Table S3), which revealed multiple resistance mutations surrounding the drug-binding pockets of each compound.
A comparison of resistance patterns between
MRTX1257 and sotorasib showed generally strong
concordance, although several drug-specific resistance mutations were identified. In addition to
differential resistance mutations observed at H95,
a greater number of MRTX1257-specific resistance mutations were observed at codons 72 and
99, a finding that is probably related to differential drug-binding interactions between MRTX1257
and sotorasib with these residues (Fig. S16A
through S16D). Although most second-site resistance mutations that were observed in the screen
occurred at residues involved in drug binding,
several mutations that were associated with resistance to both drugs were detected in amino
acids located outside the drug-binding pockets
of adagrasib and sotorasib, including known
oncogenic mutations at codons 13, 59, 61, 117,
and 146 that impede GTP hydrolysis or promote
GDP-to-GTP nucleotide exchange (Fig. 5).
In addition to the previously validated R68S,
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H95D/Q/R, and Y96C resistance mutations (Fig. 4C
through 4E), we validated the screening results
for 17 additional mutations at residues that confer resistance to one or both KRASG12C inhibitors
(Table S4). We evaluated adagrasib and sotorasib
sensitivity in Ba/F3 cells that expressed each of
these alleles (Figs. S17 and S18 and Tables S5
and S6). To enable comparison of drug resistance across different alleles and drugs, we defined a relative resistance score for each allele
according to the degree of resistance conferred
by that allele relative to the G12R mutant (Fig.
S19). As expected, the Y96C drug-binding resistance mutation showed high-level resistance to
both inhibitors, whereas the H95D, H95Q, and
H95R mutations caused resistance to adagrasib
but not to sotorasib. For both adagrasib and
sotorasib, drug-resistance mutations at residues
outside of the drug-binding pocket and known
to be involved in enhanced nucleotide exchange,
including G13D, A59S, K117N, and A146P, conferred more modest resistance than the G12R
and Y96C drug-binding mutations.
In summary, deep mutational scanning has
defined the landscape of KRAS mutations that
cause resistance to KRASG12C inhibitors. These
studies identified distinct mechanistic classes
of resistance mutations as well as drug-specific
resistance patterns.

Discussion
We performed DNA sequencing of tumor-biopsy
samples or ctDNA from 38 patients with acquired resistance to adagrasib and described putative mechanisms of resistance for 17 patients
(45%) that can be classified into three main
categories. The first category includes secondary
mutations or amplifications in KRAS, the target
of adagrasib; the second, alternative oncogenic
alterations that activate the RTK–RAS signaling
pathway but do not directly alter KRAS itself;
and the third, histologic transformation from
lung adenocarcinoma to squamous-cell carcinoma. In contrast to some targeted therapies for
which dominant mechanisms of resistance have
been observed, such as BCR-ABL mutations that
cause resistance to imatinib in chronic myeloid
leukemia,22 KRASG12C-mutant cancers appear to
evolve diverse mechanisms of resistance to adagrasib. In the majority of patients for whom we
identified a putative resistance mechanism, at
n engl j med 384;25

least one of these mechanisms did not involve
the KRAS gene itself (14 of 17 patients [82%]).
Moreover, 7 of 17 patients (41%) had more than
one concurrent potential resistance mechanism
identified, which suggests that irreversible covalent inhibition of KRASG12C leads to strong selective pressures and convergent evolution of multiple distinct mechanisms of resistance.
Acquired mutations in KRAS were observed in
7 patients, most notably at codons 12, 13, 61, 68,
95, and 96. Five patients acquired codon 12
KRAS mutations that prevent adagrasib binding,
and other secondary mutations in the switch II
drug-binding pocket were observed in 4 patients
(11% of the entire cohort) at the R68, H95, and
Y96 positions. Although the Y96C mutation appeared to be a clonal resistance event, the R68S
and H95D/Q/R secondary KRAS mutations were
identified in ctDNA at relatively low variant allele frequency as compared with that of the
KRASG12C allele and occurred in the presence of
other concurrent resistance mutations, which
suggests subclonality or heterogeneity of these
mutations across each patient’s burden of disease.
In recent work, a case was described of an acquired Y96D switch II pocket mutation identified at a low variant allele frequency in ctDNA at
the time of acquired resistance to adagrasib.23 In
our experimental studies, the R68S and Y96C
mutations confer resistance to both adagrasib
and sotorasib. In contrast, the H95D, H95Q, or
H95R adagrasib-resistance mutations do not confer in vitro resistance to sotorasib. It is notable
that the H95 adagrasib-specific resistance mutations occurred in a small number of patients (3 of
38), and each coevolved with multiple other alterations that would confer strong resistance to
both adagrasib and sotorasib. Moreover, in contrast to EGFR-mutant lung cancer, in which discovery of the dominant T790M mutation as an
on-target resistance mechanism for early-generation EGFR inhibitors led to the development of
the mutant-selective inhibitor osimertinib, the
diversity of KRAS mutations that have emerged
in response to KRASG12C inhibition may pose an
added challenge in the development of effective
next-generation inhibitors.
We also performed deep mutational scanning
screens of KRASG12C missense variants and systematically defined an atlas of KRAS mutations
that confer resistance to multiple KRASG12C inhibitors. These studies defined two apparent major
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mutational mechanisms of resistance directly involving KRASG12C. As observed clinically, mutations within the drug-binding pocket also caused
high-level resistance within our variant screening results and validation assays. Furthermore,
we identified additional second-site resistance
mutations at oncogenic hotspots that cause decreased GTP hydrolysis (e.g., G13D and Q61R) or
enhanced GDP-to-GTP nucleotide exchange (e.g.,
G13D, A59S, and A146P). These resistance mutations probably increase the fraction of KRAS
protein in the active GTP-bound form that does
not bind to the drug.4 We have not yet observed
these nucleotide-exchange resistance mutations
in clinical samples, and whether they will cause
resistance at clinically achievable concentrations
of the drug remains to be determined.
Beyond KRAS mutations, numerous additional genomic alterations in the RTK–RAS signaling
pathway were identified in 14 of 38 patients
(37% of the entire cohort). In our cohort, multiple
genomic alterations within the same patient, as
well as acquired gene fusions, appeared to be
more prevalent in colorectal cancer than in
NSCLC. It is possible that underlying differences
in genomic instability or DNA damage-response
mechanisms between colorectal cancer and
NSCLC at baseline or in response to KRAS inhibition may account for this observation. Whether
the more modest activity of KRASG12C inhibitors
in colorectal cancer is due to the earlier emergence of multiple acquired resistance mutations
or to the presence of adaptive signaling pathways
at baseline will require further investigation. The
coevolution of multiple RTK–RAS–MAPK pathway
alterations as mechanisms of adagrasib resistance strongly supports the rationale for ongoing
clinical trials of adagrasib (ClinicalTrials.gov number, NCT04330664) or sotorasib (NCT04185883)
in combination with inhibitors of RTKs or SHP2
(PTPN11) to address these adaptive resistance
mechanisms.
In two patients with NSCLC for whom we were
not able to identify a genomic resistance mechanism, we observed histologic transformation
from adenocarcinoma to squamous-cell carcinoma, which suggests that nongenetic mechanisms
of resistance to KRASG12C inhibition may occur,
similar to those observed with other targeted
therapies in lung cancer.24-26 In both patients,
deep targeted panel sequencing was performed
on the tissue sample at the time of resistance
and showed sufficient sensitivity to detect the
2392
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presence of multiple pretreatment baseline mutations in the sample, including the KRASG12C
mutation. Furthermore, one of these patients
(Patient 11) also had ctDNA sequencing at the
time of resistance that identified the KRASG12C
mutation as well as a TP53 alteration also present
in the pretreatment sample. These data suggest
that the tumor and ctDNA sequencing performed on these specimens did not miss a major
known molecular driver of adagrasib resistance,
but it remains possible that more extensive genomic sequencing of these samples could identify other acquired alterations that may have contributed to resistance. Moreover, investigation of
the genetic or epigenetic features that drive the
observed histologic conversion from adenocarcinoma to squamous-cell carcinoma may elucidate
the mechanism by which this transformation
causes resistance to KRASG12C inhibition.
The heterogeneous nature of the tumor and
ctDNA sequencing platforms that were used to
characterize acquired resistance is a limitation of
this study. Future studies of resistance mechanisms to KRAS inhibitors will benefit from using consistent sequencing platforms, as well as
analysis of matched pretreatment and postprogression biopsy samples to better define both
genetic and nongenetic mechanisms of resistance. This study focused on acquired resistance
mechanisms in patients treated with adagrasib and
did not evaluate patients treated with sotorasib.
Mechanisms of acquired resistance to sotorasib
are currently unknown; thus, direct comparison
between clinically observed adagrasib and sotorasib resistance mechanisms is not yet possible.
That said, our deep mutational scanning experiments have highlighted common and contrasting patterns of KRAS mutations that confer resistance to different KRASG12C inhibitors and
will provide a reference resource for oncologists
to interpret additional KRAS mutations that
emerge in the context of adagrasib and sotorasib
therapy.
In aggregate, these data show that a diversity
of on-target and off-target mechanisms can confer resistance to KRASG12C inhibitors and support
the need for development of additional KRAS
inhibitors with alternative modes of binding and
different allele specificities. Moreover, development of effective combination therapy regimens
will be required to fully combat resistance mechanisms that emerge during treatment with adagrasib or sotorasib.
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